Education
About Us
Working with TipRanks
Follow Us
Vaccinex Inc (VCNX)
OTHER OTC:VCNX
VCNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.25 - $8.90
Previous CloseN/A
Volume245.00
Average Volume (3M)1.62K
Market Cap
$1.87M
Enterprise Value$1.54M
Total Cash (Recent Filing)$1.11M
Total Debt (Recent Filing)$25.00K
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Aug 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,676,637
10 Day Avg. Volume1,554
30 Day Avg. Volume1,624
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.83
Price to Sales (P/S)0.00
P/FCF Ratio-0.16
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue4.95
Enterprise Value/Gross Profit-0.47
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$0.50Price Target Upside-29.58% Downside
Rating ConsensusHold
Number of Analyst Covering0
Vaccinex News
PremiumCompany Announcements
Vaccinex Delays Yearly Report Filing
Options Prices
Currently, No data available
---
Ownership Overview
51.26% Insiders
0.15% Mutual Funds
6.13% Other Institutional Investors
42.62% Public Companies and
Individual Investors
VCNX FAQ
What was Vaccinex Inc’s price range in the past 12 months?
Vaccinex Inc lowest stock price was $0.25 and its highest was $8.90 in the past 12 months.
What is Vaccinex Inc’s market cap?
Vaccinex Inc’s market cap is $1.87M.
When is Vaccinex Inc’s upcoming earnings report date?
Vaccinex Inc’s upcoming earnings report date is Aug 18, 2025 which is in 22 days.
How were Vaccinex Inc’s earnings last quarter?
Currently, no data Available
Is Vaccinex Inc overvalued?
According to Wall Street analysts Vaccinex Inc’s price is currently Overvalued.
Does Vaccinex Inc pay dividends?
Vaccinex Inc does not currently pay dividends.
What is Vaccinex Inc’s EPS estimate?
Vaccinex Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaccinex Inc have?
Vaccinex Inc has 2,676,637 shares outstanding.
What happened to Vaccinex Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaccinex Inc?
Currently, no hedge funds are holding shares in VCNX
Company Description
Vaccinex Inc
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Technical Analysis
Scinai Immunotherapeutics
―
Qualigen Therapeutics
―
Nucana
―
CNS Pharmaceuticals
―
Galecto
―